Table of Content

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines


2. EXECUTIVE SUMMARY


3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Clinical trials
3.2.1. Historical Evolution of Clinical Trials
3.2.2. Phases of Clinical Development
3.3. Introduction to Clinical Trial Planning and Design
3.3.1. Key Considerations for Clinical Trial Planning
3.3.2. Fundamentals of Clinical Trial Design
3.3.3. Challenges Associated with Clinical Trial Planning and Design
3.4. Concluding Remarks

4. REGULATORY LANDSCAPE
4.1. Chapter Overview
4.2. Regulatory Guidelines in North America
4.2.1. US Scenario
1.2.2. Canadian Scenario
4.3. Regulatory Guidelines in Europe
4.3.1. EU Scenario
4.3.2. UK Scenario
4.4. Regulatory Guidelines in Asia Pacific
4.4.1. Australian Scenario
4.4.2. Chinese Scenario
4.4.3. Indian Scenario
4.5 Concluding Remarks

5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Market Landscape of Industry Players
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Type of Product
5.2.5 Analysis by Type of Trial Design
5.2.6. Analysis by Type of Service Offered
5.3. Market Landscape for Non-Industry Players
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Location of Headquarters
5.3.4. Analysis by Type of Service Offered

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Key Assumptions and Parameters
6.3. Methodology
6.3.1. Company Competitiveness: North America
6.3.2. Company Competitiveness: Europe
6.3.3. Company Competitiveness: Asia-Pacific and RoW
6.4. Company Competitiveness: Benchmarking the Capabilities of Leading Players

7. COMPANY PROFILES
7.1. PharmaLex
7.1.1. Company Overview
7.1.2. Service Portfolio
7.1.3. Recent Development and Future Outlook
7.2. Emergo UL
7.2.1. Company Overview
7.2.2. Service Portfolio
7.2.3. Recent Development and Future Outlook
7.3. Cytel
7.3.1. Company Overview
7.3.2. Service Portfolio
7.3.3. Recent Development and Future Outlook
7.4. Health Policy Associate
7.4.1. Company Overview
7.4.2. Service Portfolio
7.4.3. Recent Development and Future Outlook
7.5. CD BioSciences
7.5.1. Company Overview
7.5.2. Service Portfolio
7.5.3. Recent Development and Future Outlook
7.6. LLX Solutions
7.6.1. Company Overview
7.6.2. Service Portfolio
7.6.3. Recent Development and Future Outlook
7.7. SGS
7.7.1. Company Overview
7.7.2. Service Portfolio
7.7.3. Recent Development and Future Outlook
7.8. ADM Korea
7.8.1. Company Overview
7.8.2. Service Portfolio
7.8.3. Recent Development and Future Outlook
7.9. ClinAsia
7.9.1. Company Overview
7.9.2. Service Portfolio
7.9.3. Recent Development and Future Outlook
7.10. BioPoint
7.10.1. Company Overview
7.10.2. Service Portfolio
7.10.3. Recent Development and Future Outlook

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Clinical Trial Planning and Design: Recent Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Focus Area
8.4. Most Active Players: Analysis by Number of Partnerships
8.5. Analysis by Geography
8.5.1. Country-wise Distribution
8.5.2. Intercontinental and Intracontinental Deals

9. MERGERS AND ACQUISITIONS
9.1. Chapter Overview
9.2. Merger and Acquisition Models
9.3. Clinical Trial Planning and Design: Mergers and Acquisitions
9.3.1. Analysis by Year of Agreement
9.3.2. Analysis by Type of Agreement
9.3.3. Analysis by Type of Acquisition
9.3.4. Analysis by Geography
9.3.4.1. Region-wise distribution
9.3.4.2. Country-wise distribution
9.3.3. Ownership Type Change Matrix
9.4. Key Value Drivers
9.4.1. Analysis by Key Value Drivers
9.4.2. Analysis by Year of Acquisition and Key Value Drivers

10. ATTRACTIVENESS COMPETETIVENESS MATRIX
10.1. Chapter Overview
10.2. AC Matrix: Overview
10.2.1. Strong Business Segment
10.2.2. Average Business Segment
10.2.3. Weak Business Segment
10.3. Analytical Methodology
10.4. AC Matrix: Clinical Planning and Design Scenario in North America
10.5. AC Matrix: Clinical Planning and Design Scenario in Europe
10.6. AC Matrix: Clinical Planning and Design Scenario in Asia Pacific and Middle East

11. COST SAVING ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions
11.3. Methodology
11.4. Overall Cost Saving Potential of Clinical Trial Planning and Design, 2021-2030
11.5. Concluding Remarks

12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Clinical Trial Planning and Design Market
12.3.1. Global Clinical Trial Planning and Design Market: Distribution by Type of Service Offered
12.3.2. Global Clinical Trial Planning and Design Market: Distribution by Therapeutic Area
12.3.3. Global Clinical Trial Planning and Design Market: Distribution by Trial Phase
12.3.4. Global Clinical Trial Planning and Design Market: Distribution by Geography
12.4. Clinical Trial Planning and Design Market in North America
12.4.1. Clinical Trial Planning and Design Market in North America: Distribution by Therapeutic Area
12.4.1.1. Clinical Trial Planning and Design Market for Oncological Disorders in North America, 2021-2030
12.4.1.2. Clinical Trial Planning and Design Market for Neurological Disorders in North America, 2021-2030
12.4.1.3. Clinical Trial Planning and Design Market for Infectious Disorders in North America, 2021-2030
12.4.1.4. Clinical Trial Planning and Design Market for Autoimmune Disorders in North America, 2021-2030
12.4.1.5. Clinical Trial Planning and Design Market for Cardiovascular Disorders in North America, 2021-2030
12.4.1.6. Clinical Trial Planning and Design Market for Respiratory Disorders in North America, 2021-2030
12.4.1.7. Clinical Trial Planning and Design Market for Other Therapeutic Areas in North America, 2021-2030
12.5. Clinical Trial Planning and Design Services Market in Europe
12.5.1. Clinical Trial Planning and Design Services Market: Distribution by Therapeutic Area in Europe
12.5.1.1. Clinical Trial Planning and Design Market for Oncological Disorders in Europe, 2021-2030
12.5.1.2. Clinical Trial Planning and Design Market for Neurological Disorders in Europe, 2021-2030
12.5.1.3. Clinical Trial Planning and Design Market for Infectious Disorders in Europe, 2021-2030
12.5.1.4. Clinical Trial Planning and Design Market for Autoimmune Disorders in Europe, 2021-2030
12.5.1.5. Clinical Trial Planning and Design Market for Cardiovascular Disorders in Europe, 2021-2030
12.5.1.6. Clinical Trial Planning and Design Market for Respiratory Disorders in Europe, 2021-2030
12.5.1.7. Clinical Trial Planning and Design Market for Other Therapeutic Areas in Europe, 2021-2030
12.6. Clinical Trial Planning and Design Services Market in Asia-Pacific
12.6.1. Clinical Trial Planning and Design Services Market: Distribution by Therapeutic Area in Asia-Pacific
12.6.1.1. Clinical Trial Planning and Design Market for Oncological Disorders in Asia-Pacific, 2021-2030
12.6.1.2. Clinical Trial Planning and Design Market for Neurological Disorders in Asia-Pacific, 2021-2030
12.6.1.3. Clinical Trial Planning and Design Market for Infectious Disorders in Asia-Pacific, 2021-2030
12.6.1.4. Clinical Trial Planning and Design Market for Autoimmune Disorders in Asia-Pacific, 2021-2030
12.6.1.5. Clinical Trial Planning and Design Market for Cardiovascular Disorders in Asia-Pacific, 2021-2030
12.6.1.6. Clinical Trial Planning and Design Market for Respiratory Disorders in Asia-Pacific, 2021-2030
12.6.1.7. Clinical Trial Planning and Design Market for Other Therapeutic Areas in Asia-Pacific, 2021-2030
12.7. Clinical Trial Planning and Design Services Market in Latin America
12.8. Clinical Trial Planning and Design Services Market in Middle East North America
13. SWOT ANALYSIS
13.1. Chapter Overview
13.2. Strengths
13.3. Weaknesses
13.4. Opportunities
13.5. Threats
13.6. Comparison of SWOT Factors
14. CONCLUDING REMARKS
15. EXECUTIVE INSIGHTS
15.1 Chapter Overview
15.2 Armstrong Clinical
15.2.1 Company Snapshot
15.2.2 Interview Transcript: Bradley Joblin, Study Design and Clinical Development Specialist
15.3 Interdisciplinary Health Sciences Institute (University of Illinois)
15.3.1 Company Snapshot
15.3.2 Interview Transcript: Jesus N. Sarol Jr (Senior Research Biostatistician) and Amandeep kaur (Research Biostatistician)

16. APPENDIX I: LIST OF CROS

17. APPENDIX II: TABULATED DATA

18. APPENDIX III: LIST OF COMPANIES AND ORGANIZATION